Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Mingshan Niu"'
Autor:
Ting Pan, Lingling Yin, Huanxin Zhang, Kailin Xu, Zhenyu Li, Ninghan Zhang, Qing-Yun Wu, Shengyun Zhu, Rong Wang, Jiawen Xu, Linyan Xu, Xuejiao Liu, Mingshan Niu, Yao Yao
Publikováno v:
Journal of Molecular Medicine. 99:1447-1458
The NF-κB signaling pathway is an important downstream pathway of oncogenic Notch1 in T cell acute lymphoblastic leukemia (T-ALL) cells. However, the molecular mechanisms underlying the cascade activation of Notch1 in T-ALL cells are poorly understo
Autor:
Yang Jiao, Yifan Pang, Yifeng Dai, Lingxiu Zhang, Jinlong Shi, Mingshan Niu, Zhiheng Cheng, Sun Wu, Lihua Wang, Lin Fu, Yuan Zhang, Xiaoyan Ke, Dong Ma, Xiufeng Wang, Kailin Xu
Publikováno v:
Cancer Gene Therapy, 25(7-8), 207-213. Nature Publishing Group
The mutational spectrum and prognostic stratification of intermediate-risk acute myeloid leukemia (IR-AML), which accounts for a substantial number of AML, are unclear. In order to explore the prognostic significance of the mutational spectrum in IR-
Autor:
Mingshan Niu, Wei Chen, Jiang Cao, Wei Sang, Xuejiao Liu, Yao Yao, Kailin Xu, Qing-Yun Wu, Yangling Shen, Jialei Qi
Publikováno v:
Annals of Hematology. 96:1945-1948
Autor:
Hongmei Liu, Zhenglei Qi, Huize Liu, Yao Yao, Yiming Tu, Ning Liu, Shangfeng Gao, Chenglong Yue, Rutong Yu, Yulong Chong, Xuejiao Liu, Mingshan Niu
Publikováno v:
Journal of Hematology & Oncology, Vol 9, Iss 1, Pp 1-14 (2016)
Journal of Hematology & Oncology
Journal of Hematology & Oncology
Background Malignant gliomas are associated with a high mortality rate, and effective treatment options are limited. Thus, the development of novel targeted treatments to battle this deadly disease is imperative. Methods In this study, we investigate
Autor:
Xiaomin Zhong, Chunling Fu, Mingshan Niu, Jianlin Qiao, Feng Zhu, Wei Chen, Lingyu Zeng, Qing-Yun Wu, Zhenyu Li, Kailin Xu, Yao Yao
Publikováno v:
Medical Oncology. 32
Antithymocyte globulin (ATG) combined with cyclosporine A (CsA) has been widely used as a standard regimen in the treatment of aplastic anemia (AA), especially in severe aplastic anemia (SAA). Abnormally activated T cells might be the immune pathogen